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Abstract
This study investigates the effect of the selective Jun NH2-terminal kinase 1/2 (JNK1/2) inhibitor, (SP600125) on
the striatal dopamine nerve terminal loss and on the increased interleukin-15 (IL-15) expression and glial
response induced by methamphetamine (METH). Mice were given repeated low doses of METH (4mg/kg,
i.p., three times separated by 3 h) and killed 24 h or 7 d after the last dose. SP600125 (30mg/kg, i.p) was ad-
ministered 30min before the last METH injection. Results indicate that METH produced dopaminergic axonal
neurotoxicity reﬂected as a marked decrease in the striatal density of tyrosine hydroxylase-immunoreactive
(TH-ir) ﬁbres and dopamine transporter-immunoreactivity (DAT-ir) 24 h after dosing. These effects were not
modiﬁed by SP600125. This compound also failed to prevent the long-term loss of dopamine levels and DAT
observed 7 d following METH injection. Nevertheless, SP600125 potentiated METH-induced striatal cell loss
reﬂected by an increase in Fluoro-Jade immunostaining, cleaved capase-3 immunoreactivity and the number
of terminal deoxyncleotidyl transferase-mediated dUTP nick end labelling (TUNEL) positive cells. In line with
a deleterious effect of JNK1/2 inhibition, SP600125 increased the astroglial and microglial response induced by
METH and interfered with drug-induced IL-15 expression. Together these data indicate that, not only does
SP600125 fail to protect against the dopaminergic damage induced by METH but also, in fact, it potentiates
the glial response and the non-dopaminergic striatal cell loss caused by the drug.
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Introduction
Methamphetamine (METH) is a powerful psycho-
stimulant with high abuse potential (UNODC, 2012).
In mice, repeated administration of METH produces
dopaminergic neurodegeneration consisting in the loss
of axons and terminals in the striatum and of cell bodies
in the substantia nigra (Hirata and Cadet, 1997; Krasnova
and Cadet, 2009; Granado et al., 2010). Numerous studies
have shown a long-term substantial decrease in the con-
centration of dopamine and its metabolites, a loss in the
density of plasmalemmal and vesicular dopamine trans-
porters and a decrease in tyrosine hydroxylase activity
(Sonsalla et al., 1989; O’Callaghan and Miller, 1994;
Hogan et al., 2000; Itzhak et al., 2000; Ares-Santos et al.,
2012). In addition, METH administration induces reactive
astrocytosis and microgliosis and increases interleukin-15
(IL-15) expression (Thomas et al., 2004b, 2008; Granado
et al., 2011a,b).
The mechanisms underlying this toxicity are still
unknown but it appears that several factors are involved
including; oxidative stress, neuroinﬂammatory processes,
hyperthermia and mitochondrial/endoplasmic reticulum
stress (Itzhak et al., 1998, 2000; Deng and Cadet, 1999;
Imam et al., 2001; Krasnova and Cadet, 2009).
We have recently shown that repeated administration
of low-dose METH disrupts the integrity of the blood-
brain barrier (BBB) (Urrutia et al., 2013). Thus, shortly
after METH treatment there is a reduction in striatal
laminin expression and increased immunoglobulin (IgG)
immunoreactivity colocalizing with areas of greater
matrix metallopeptidase-9 (MMP-9) activity. Adminis-
tration of the JNK1/2 inhibitor, SP600125, prevented all
these changes and attenuated the increased expression
of p-JNK1/2 induced by the drug (Urrutia et al., 2013).
In addition, METH generates a differential regulation
of endothelial (ABC) transporters, which is controlled
by apolioprotion-E (ApoE), most probably through its
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receptor ApoER2 that deactivates the JNK1/2/c-Jun
pathway in brain endothelial cells (ElAli et al., 2012).
Together, these data indicate that METH induces signiﬁ-
cant changes in BBB structure and function through the
JNK pathway.
It is well known that JNK is linked to parenchymal
stress and it has been associated with dopaminergic
neurotoxicity in experimental models of Parkinson’s
disease (Saporito et al., 1999; Hunot et al., 2004; Wang
et al., 2004) as well as cellular damage in a wide variety
of experimental models such as ischaemic stroke
(Borsello et al., 2003), spinal cord injury (Repici et al.,
2012) and Alzheimer’s disease (Morishima et al., 2001)
among others, thus becoming a promising target for the
treatment of neurodegenerative diseases.
The role of JNK signalling in in vivo METH-induced
neuronal damage has been scarcely investigated with
only one study showing that a single high dose of
METH induces extensive apoptosis in the mouse brain,
which is less evident in c-Jun knockout mice. METH-
induced caspase-3 activity and Poly (ADP-ribose) poly-
merase (PARP) cleavage were also reduced in c-Jun
heterozygous knockout mice (Deng et al., 2002).
The present study was undertaken to determine:
(1) the ability of the selective JNK1/2 inhibitor SP600125
to prevent the striatal loss of dopamine nerve terminals
induced by METH by assessing tyrosine hydroxylase
(TH) and dopamine transporter (DAT) expression and
dopamine concentration; (2) the role of SP600125 in the
METH-induced striatal cell loss evaluated by counting
Fluoro-Jade and terminal deoxyncleotidyl transferase-
mediated dUTP nick end labelling (TUNEL) positive
cells as well as expression of cleaved caspase-3; and
(3) the effect of SP600125 on the METH-induced IL-15
expression and microglial and astroglial response by
determining Iba-1 and glial ﬁbrillary acidic protein anti-
body (GFAP) immunoreactivity in striatum.
Materials and method
Animals and drug administration
Adult male C57BL/6J mice (25–30 g, Harlan Laboratories
Models, Barcelona) were used. Animals were housed
in groups of 4–6 in conditions of constant temperature
(21 °C±2 °C) in a 12 h light/dark cycle (lights on: 08 h
00min) and given free access to food and water.
Mice received a neurotoxic regimen of three injections
of (+)-METH (4mg/kg, i.p.) at 3 h intervals and were
killed 24 h or 7 d after drug dosing. Doses and protocol
of administration were previously shown to produce a
marked depletion of mouse striatal dopamine (Sanchez
et al., 2003; Granado et al., 2010, 2011a; Ares-Santos
et al., 2012). The time-points were chosen since METH
produces an early loss of several dopaminergic par-
ameters at 24 h, a time-point that is also suitable for
glial determination. Seven days after METH a marked
depletion of dopamine and dopamine transporters sites
is observed and is commonly used as a time-point for as-
sessing neurotoxicity (Sanchez et al., 2003; Granado et al.,
2011a; Ares-Santos et al., 2012). METH hydrochloride
(Sigma-Aldrich, USA) was dissolved in 0.9% w/v NaCl
(saline) and injected in a volume of 10ml/kg. The JNK
inhibitor SP600125 (30mg/kg, i.p.) was administered 30
min before the last METH injection and was dissolved
in 20% DMSO in saline solution (Urrutia et al., 2013).
All experimental procedures were performed in accor-
dance with the guidelines of the Animal Welfare Com-
mittee of the Universidad Complutense of Madrid
(following European Council Directives 86/609/CEE and
2003/65/CE).
Measurement of monoamines and metabolites
in striatum
Seven d after treatment, the mice were killed by cervical
dislocation and decapitation, the brains were rapidly re-
moved and the striatum dissected out on ice. Dopamine
(DA), and the metabolites 3,4-dihydroxyphenylacetic
acid (DOPAC) and homovanillic acid (HVA) were
measured by high-performance liquid chromatography
(HPLC) and electrochemical detection. The mobile
phase consisted of (KH2PO4: 0.05 M), octanesulfonic acid
(0.4 mM), EDTA (0.1 mM) and methanol (16%) and was
adjusted to pH 3 with phosphoric acid, ﬁltered and
degassed. The ﬂow rate was 1ml/min. The HPLC system
consisted of a pump (Waters 510) linked to an automatic
sample injector (Loop 200 μl, Waters 717 plus auto-
sampler) and a stainless steel reversed-phase column
(Spherisorb ODS2, 5 μM, 150×4.6 mm; Waters, USA) with
a pre-column and a coulometric detector (Coulochem II;
USA). The working electrode potential was set at
400mV with a gain of 1 μA (for dopamine) and 500 nA
(for the remaining compounds). The current produced
was monitored by means of integration software
(Clarity Software, DataApex, Czech Republic).
[3H]-WIN 35,428 binding
[3H]WIN 35428 binding was measured by modiﬁcation of
the method described in detail by Segal et al., (2003) and
used as an index of dopamine transporter density. One
week after METH administration, the animals were killed
and their brains were rapidly removed and the striatum
dissected out on ice. Striata were sonicated in ice-cold
sodium phosphate buffer (20mM; pH 7.4) containing
sucrose (0.32 M). The homogenate was centrifuged at
30000 g for 15min at 4 °C. The supernatant was dis-
carded and the wash procedure was repeated twice
more. The pellet was ﬁnally re-suspended in 60 volumes
of homogenization buffer. The assay solution (500 μl) con-
tained [3H]WIN 35428 (5 nM), desipramine (300 nM) and
100 μl tissue preparation (approx. 80 μg protein). Non-
speciﬁc binding was carried out in the presence of cocaine
(30 μM). The reaction mixture was incubated for 90min
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at 4 °C. The assay was terminated by rapid ﬁltration,
and radioactivity was counted by scintillation spectro-
metry.
Immunohistochemistry
One day after the administration of METH (4mg/kg, i.p. 3
times, at 3 h intervals), animals were deeply anaesthetized
(sodium pentobarbital, 50mg/kg,) and transcardially per-
fused with 4% paraformaldehyde. Immunostaining was
carried out in free-ﬂoating brain sections (30 μM) with
standard avidin–biotin immunohistochemical protocols
(Granado et al., 2008), with speciﬁc TH antisera (1:1000;
Chemicon International, USA) or DAT monoclonal anti-
body (1:5000; Chemicon International). After incubation
with the primary (overnight) and secondary antisera
(1 h; Vector Laboratories) peroxidase reactions were de-
veloped in diaminobenzidine. For immunoﬂuorescence
studies, slices were incubated with rabbit anti- GFAP
(1:1000, DakoCytomation, Denmark), rabbit anti-Iba-1
(1:1000, Wako Pure Chemical Industries, Japan); and poly-
clonal goat anti-IL-15 (1:200, Santa Cruz Biotechnologies,
USA), incubated with the corresponding secondary
antibodies (AlexaFluor™ 1:1000) and covered with
ProLong®Gold (Invitrogen).
Quantiﬁcation of TH and DAT striatal expression
was performed with the aid of an image analysis system
(Image J: National Institutes of Health, USA) using a 5×
lens. The data are presented as the proportional stained
area (total TH- or DAT-positive area/scan area) in the
striatal compartments. For immunoﬂuorescence quan-
tiﬁcation, images taken at 20× lenses were converted to
grey scale, and the integrated density within each region
of interest for each section was measured with ImageJ.
Measurements were carried out in at least 5 animals per
treatment (5–6 sections/animal).
Fluoro-Jade C staining
Coronal brain sections (30 μM) were obtained on a
slicing vibratome as described above. The sections were
mounted on gelatin-coated slides and allowed to dry
fully for 20min after which they were immersed in
100% ethyl alcohol for 3min followed by a 1min soak
in 70% alcohol and a 1min soak in distilled water. The
slides were then transferred to a solution of 0.06% potass-
ium permanganate for 15min. The slides were rinsed for
1min in distilled water and were then transferred to the
Fluoro-Jade staining solution where they were gently
agitated for 30min. The 0.001% working solution of
Fluoro-Jade was prepared by adding 10ml of the stock
Fluoro-Jade solution (0.01%) to 90ml of 0.1% acetic acid
in distilled water (Schmued et al., 2005; Granado et al.,
2011b). After staining, sections were rinsed 3 times for
1min each with fresh changes of distilled water. Excess
water was drained off. When dry, the slides were im-
mersed in xylene and cover slipped with D.P.X. mounting
media (VWR international). Striatal sections were
examined with a ﬂuorescence microscope using a ﬁlter
system suitable for visualizing ﬂuorescein or (FITC).
Two different observers counted the Fluoro-Jade positive
cells manually.
TUNEL histochemistry
TUNEL histochemistry was carried out in situ with the
Cell Detection Kit, POD, according to the manufacturer’s
instructions (Roche, Spain), with minor modiﬁcations.
In brief, ﬁxed sections were washed and boiled in a
microwave for 1min at 750W in 0.1 M citrate buffer
pH=6.0. After blocking with PBS buffer containing 3%
BSA and 0.1% Triton X-100, sections were washed and
incubated with the TUNEL reaction mixture at 37 °C,
washed again and incubated with Converter POD at
37 °C. Next, the sections were washed to remove excess
Converter POD, developed with DAB-nickel, covered
and analyzed under light microscopy. Positive (DNAse)
and negative controls (without TUNEL reaction mix-
ture) were processed in parallel with the experimental
groups.
Cleaved caspase-3 Western blot
Mice were killed by cervical dislocation and decapitation
24 h after METH administration, and striata dissected out
on ice. Striata were homogenized in buffer containing
50mM Tris–HCl (pH 7.4), 150mM NaCl, 1 mM (EGTA),
0.2% NP-40, supplemented with 5% protease and 1%
phosphatase inhibitor cocktail (Sigma-Aldrich, USA)
and centrifuged at 20000 g for 15min and the super-
natant was collected. Equal amounts of protein (35 μg)
were boiled in laemmli buffer, resolved by 12% sodium
dodecyl sulfate polyacrylamide gel electrophoresis
(SDS–PAGE) and transferred to polyvinylidene diﬂuoride
(PVDF) membranes. Non-speciﬁc binding was blocked
with TBS buffer containing 0.1% Tween 20 and 5%
skimmed milk. Membranes were incubated overnight at
4 °C with anti-cleaved Caspase-3 (Asp175) (Cell Signall-
ing; 1:1000) or anti-β-actin (Sigma-Aldrich, 1:1000) pri-
mary antibodies followed by incubation with donkey
anti-rabbit IgG-horseradish peroxidase (Sigma-Aldrich;
1:3000) or goat anti-mouse IgG-horseradish peroxidase
(GE Healthcare, Spain; 1:5000) antibodies for 1 h. Each
band density was normalized by referring it to its
β-actin band density.
Statistics
Data are presented as mean±standard error of the
mean (S.E.M.). All results were analyzed using
one-way ANOVA) followed by Newman–Keuls multiple-
comparisons test when a signiﬁcant F value was obtained
(GraphPad Prism 5.0, GraphPad Software Inc., USA).
Differences were considered signiﬁcant at p<0.05.
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Results
METH-induced striatal dopaminergic toxicity is not
prevented by SP600125
Consistent with previous reports (Granado et al.,
2011a,b), repeated administration of METH (4mg/kg,
i.p., three times at 3 h intervals) produced dopaminergic
axonal neurotoxicity reﬂected as a marked decrease in
the density of TH-ir ﬁbres in striatum 24 h after dosing
(Fig. 1a). This loss of striatal TH-ir was not modiﬁed by
the JNK inhibitor SP600125 (30mg/kg, i.p. 30min before
last METH injection).
Quantitative image analysis by one-way ANOVA
revealed a signiﬁcant effect of treatment (Fig. 1b; F3,19=
87.63, p<0.0001). Post-hoc analysis indicated that METH
produced a signiﬁcant reduction (81%, Fig. 1b) in TH-ir
that was not altered by co-administration of SP600125
(75%, Fig. 1b). SP600125 did not produce any effect in
the saline-treated group.
As expected, the pattern of DAT-immunoreactive
(DAT-ir) loss produced by METH was very similar to
the pattern of TH-ir loss, with a homogeneous decrease
in DAT-ir ﬁbres along the rostro-caudal axis and a greater
loss of DAT-ir ﬁbres in the lateral parts of the striatum
(Fig. 2a). This effect was not modiﬁed by the JNK inhibi-
tor SP600125.
Quantitative image analysis by one-way ANOVA
revealed a signiﬁcant effect of treatment (Fig. 2b; F3,19=
790.9, p<0.0001). Post-hoc analysis indicated that METH
produced a signiﬁcant reduction (96%, Fig. 2b) in
DAT-ir that was not altered by co-administration of
SP600125 (92%, Fig. 2b). SP600125 did not produce any
effect in the saline-treated group.
To evaluate the effect of SP600125 on the long-term
loss of dopamine nerve terminals induced by METH,
we determined the concentration of dopamine and meta-
bolites and the density of dopamine transporters 7 d after
METH dosing. One-way ANOVA revealed a signiﬁcant
effect of treatment on dopamine (Fig. 3a, F3,21=89.17,
p<0.0001), DOPAC (Fig. 3c, F3,23=85.18, p<0.0001) and
HVA (Fig. 3d, F3,21=69.04, p<0.0001) and on dopamine
transporter number (Fig. 3b, F3,15=9.38, p<0.001).
Post-hoc analysis indicated that METH reduced all these
parameters (77% for DA, 78% for DOPAC, 55% for HVA
and 48% for the dopamine transporter), an effect that
was not modiﬁed by the co-administration of SP600125.
SP600125 administration exacerbates METH-induced
striatal cell loss
Fluoro-Jade stains cell bodies, dendrites, and axon ter-
minals of degenerating neurons without staining healthy
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Fig. 1. SP600125 (SP, 30mg/kg i.p.) does not modify the decrease in striatal TH-immunoreactivity induced by METH (4mg/kg, i.p.,
3 times at 3 h intervals). SP600125 was administered 30min before the last dose of METH. (a) Photomicrographs of striatal sections
stained for TH from mice 24 h after treatment. (b) Histogram shows the proportional stained area of TH immunoreactivity staining
in the striatum. Data represent mean±S.E.M., n=5–7 per group. ***p<0.001 vs. saline, one-way ANOVA followed by Newman–Keuls
test. Bar indicates 500 μM.
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neurons (Schmued et al., 2005; Granado et al., 2008,
2011b). Figure 4a illustrates a representative image of
Fluoro-Jade staining 24 h after METH treatment. One-
way ANOVA revealed a signiﬁcant effect of treatment
(Fig. 4b; F3,16=13.65, p<0.0001). Post-hoc analysis indi-
cated that METH increased the number of Fluoro-Jade
stained cells (159%) in striatum and that this effect
was greater in mice treated with METH and SP600125
(353%). SP600125 had no effect in the saline-treated
group.
In order to conﬁrm the results obtained with Fluro-
Jade staining we determined DNA fragmentation by
TUNEL histochemistry and cleaved caspase-3 expression
by Western blot. Figure 5a illustrates a representative
image of TUNEL histochemistry 24 h after METH treat-
ment. One-way ANOVA revealed a signiﬁcant effect
of treatment (Fig. 5b; F3,16=35.64, p<0.0001). Post-hoc
analysis indicated that METH increased the number of
TUNEL positive cells (240%) in striatum and that this
effect was greater in mice treated with METH and
SP600125 (740%). SP600125 had no effect in the saline-
treated group. One of the main executioners of apoptosis
is caspase-3 in its activated (cleaved) 17 kDa form.
Figure 5c shows a representative Western blot of cleaved
caspase-3. One-way ANOVA revealed a signiﬁcant effect
of treatment (Fig. 5d; F3,15=8.31, p=0.0017). Post-hoc
analysis indicated that mice treated with METH and
SP600125 showed increased cleaved caspase-3 immuno-
reactivity (120%) in striatum compared with saline-
treated animals and this was signiﬁcantly greater than
that produced by METH alone (50%). SP600125 had no
effect in the saline-treated group.
SP600125 increases METH-induced glial response
Glial response has generated great interest, since it is
thought to be mediator of amphetamine-like substances
neurotoxicity (Thomas et al., 2004a; Yamamoto et al.,
2010). We have previously shown that following METH
there is an increase in the astroglial and the microglial
response. Therefore, we investigated the ability of
SP600125 to modify the effect of METH on immunoﬂuor-
escence staining for GFAP and ionized calcium binding
adaptor molecule 1 (Iba-1), markers for astrogliosis and
microgliosis, respectively. Figures 6a and 7a illustrate a
representative image of GFAP and Iba-1 staining 24 h
after METH treatment.
With respect to the astroglial response, one-way
ANOVA revealed a signiﬁcant effect of treatment
(Fig. 6b; F3,16=24.99, p<0.0001). Post-hoc analysis indi-
cated that METH increased the number of GFAP staining
(130%) in the striatum and that this effect was greater
in mice treated with METH and SP600125 (227%).
SP600125 had no effect in the saline-treated group.
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Fig. 2. SP600125 (SP, 30mg/kg, i.p.) does not modify the decrease in striatal DAT-immunoreactivity induced by METH (4mg/kg,
i.p., 3 times at 3 h intervals). SP600125 was administered 30min before the last dose of METH. (a) Photomicrographs of striatal
sections stained for DAT from mice 24 h after treatment. (b) Histogram shows the proportional stained area of DAT
immunoreactivity staining in the striatum. Data represent mean±S.E.M., n=5–7 per group. ***p<0.001 vs. saline, one-way ANOVA
followed by Newman–Keuls test. Bar indicates 500 μM.
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It should be noted that, not only is the number of astro-
cytes increased, but their shape, indicative of different
properties, is also altered becoming more activated
as their form turns to a more ameboid phenotype. This
effect was more evident in the SP600125+METH group
compared with those receiving METH alone. These data
indicate that treatment with METH induces enhanced
astrogliosis in the presence of the inhibitor of JNK,
SP600125.
Regarding Iba-1 immunoreactivity, one-way ANOVA
revealed a signiﬁcant effect of treatment (Fig. 7b; F3,16=
12.18, p<0.0002). Post-hoc analysis indicated that METH
increased the number of Iba-1 staining cells (130%) in
striatum and that this effect was greater in mice treated
with METH and SP600125 (248%). In this latter group,
cells developed into a more activated phenotype reﬂected
by shorter ramiﬁcations and an enlarged nucleus
(shown in the magniﬁed microphotography). SP600125
had no effect in the saline-treated group.
Taken together, these data demonstrate that inhibition
of JNK by SP600125 increased the astrocytic and micro-
glial responses in the striatum of mice treated with
METH.
SP600125 reduces the METH-induced increase in
IL-15 expression
We also examined the expression of IL-15, an early
marker of neuroinﬂammation (Gómez-Nicola et al.,
2008) that we have previously shown to colocalize with
GFAP positive cells (Granado et al., 2011b). Figure 8a
illustrates a representative image of IL-15 24 h after
METH treatment. One-way ANOVA revealed a signiﬁ-
cant effect of treatment (Fig. 8b F3 16=5.03, p=0.0121).
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Fig. 3. SP600125 (SP, 30mg/kg i.p.) does not modify the loss of striatal dopamine (a), DAT (b), DOPAC (c) HVA (d ) induced by
METH (4mg/kg, i.p., 3 times at 3 h intervals) seven days after treatment. SP600125 was administered 30min before the last dose
of METH. Data represent mean±S.E.M., n=5–8 per group. *p<0.05, ***p<0.001 vs. saline; one-way ANOVA followed by
Newman–Keuls test.
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Post-hoc analysis indicated that METH increased IL-15
immunoreactivity (23%), an effect that was abolished in
mice treated with METH and SP600125. SP600125 alone
had no effect in saline-treated mice.
Discussion
A previous study (Urrutia et al., 2013) showed that
repeated administration of METH to mice reduces BBB
integrity. One hour after METH treatment there is a
reduction in laminin expression and an increase in IgG
immunoreactivity and in MMP-9 expression and activity,
which colocalizes with areas of greater IgG immuno-
reactivity. The effect on IgG expression is still evident
24 h after dosing. Injection of the JNK inhibitor,
SP600125, 30min before the last METH administration
prevented METH-induced changes in MMP-9 activity,
laminin degradation and BBB leakage. SP600125 was
also able to prevent the increased p-JNK1/2 expression
induced by the drug 1 h after injection. Studies have
shown that disruption of BBB is implicated in a large num-
ber of neurodegenerative disorders (Zlokovic, 2008).
Therefore, the overall aim of the current study was to
investigate the effect of the selective JNK1/2 inhibitor
SP600125 on the striatal loss of dopamine nerve terminals
and on the increased IL-15 expression and glial response
induced by METH.
Results reported here conﬁrm that repeated doses of
METH induce long-term neurotoxicity and demonstrate
that this effect is not prevented by co-administration of
SP600125. Seven d after METH injection there is a loss
of striatal concentration of dopamine, DOPAC, HVA
and density of dopamine transporters, which is similar
to that observed in mice receiving METH plus
SP600125. The JNK inhibitor not only fails to provide pro-
tection against the METH-induced long-term toxicity but
also is unable to prevent the reduction in TH- and DAT-ir
produced by METH 24 h after dosing. Considering that
SP600125 is able to prevent the increased p-JNK1/2
expression induced by METH, results reported in this
study indicate that the JNK pathway may not be involved
in the striatal dopaminergic neurotoxicity induced by
METH.
There are relatively few studies reporting the effect of
SP600125 on the dopamine neuronal damage induced
by other neurotoxins such as MPTP or 6-OHDA. Results
show that SP600125, in addition to reducing MPTP-
induced c-Jun phosphorylation, restores the level of TH
expression and reduces the loss of TH-positive neurons
of SNc (Wang et al., 2004, 2009). It is worth mentioning
that in the aforementioned studies, although adminis-
tered at the same dose as in the current study, SP600125
was injected once daily over 5 consecutive days and co-
inciding with MPTP injections. However, in our model
we were unable to use repeated doses since SP600125
administration 30min before each of the three METH
injections induced a mortality of nearly 80% (data not
shown).
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Fig. 4. SP600125 (SP, 30mg/kg i.p.) potentiates the striatal neuron loss induced by METH (4mg/kg i.p., 3 times at 3 h intervals).
SP600125 was administered 30min before the last dose of METH. (a) Photomicrograph of striatal sections stained for Fluoro-Jade
from mice 24 h after treatment. (b) Histogram shows the number of Fluoro Jade-positive cell bodies. Data represent mean±S.E.M.,
n=4–7 per group. *p<0.05, ***p<0.001 vs. saline; ΔΔp<0.01 vs. METH-treated group, one-way ANOVA followed by Newman–Keuls
test. Bar indicates 100 μM.
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It is clear that JNK plays a role in neurodegeneration,
speciﬁcally in models of Parkinson disease, and is a puta-
tive therapeutic target for preventing neuronal death.
However, the JNK pathway does not appear to par-
ticipate in axonal degeneration (Ries et al., 2008) so
other therapeutic targets will need to be identiﬁed to
halt that component of the degenerative process. There
is now substantial evidence that the molecular pathways
underlying destruction of the cell soma are separate and
distinct from those, which mediate destruction of axons
(Raff et al., 2002; Coleman, 2005).
It is also relevant to consider that the down-stream fac-
tors involved in MPTP damage are not the same as those
in METH damage. It has been described that COX2 is a
molecular target of JNK activation in mesencephalon
and it is essential for MPTP-induced dopaminergic cell
death (Hunot et al., 2004). Our results show that follow-
ing METH there is no change in the striatal expression
of COX2 (Supplementary Figure S1).
In recent years it has been demonstrated that apart
from classical monoaminergic toxicity, METH induces
non-monoaminergic neuronal soma degeneration in the
striatum of rodents (Jayanthi et al., 2004, 2005; Zhu
et al., 2009). The affected cells have been identiﬁed as
the GABAergic neurons expressing enkephalin and parv-
albumin (Jayanthi et al., 2005; Thiriet et al., 2005). Support-
ing these observations, and as previously reported
(Granado et al., 2011b), repeated METH administration
resulted in the appearance of Fluoro-Jade positive im-
munostaining in striatum, a marker of degenerating
neurons (Schmued et al., 2005). Interestingly, not only
did SP600125 fail to prevent the striatal cell loss induced
by METH, it increased the number of Fluoro-Jade and
TUNEL positive cells and the cleavage of caspase-3
supporting a survival role of JNK pathway activation
in METH-induced striatal neuronal degeneration.
In line with this, data in the literature indicate that the
JNK pathway also participates in the regulation of cell
proliferation, survival and differentiation (Davis, 2000)
suggesting that JNK also carries out physiological func-
tions, substantial levels of JNK expression and activity
can be detected in the striatum of untreated mice (ElAli
et al., 2012; Urrutia et al., 2013). Several factors appear
to be involved in the different consequences of JNK ac-
tivation including the intensity or duration of a signal
with transient JNK activation promoting cell survival
and prolonged JNK activation inducing cellular apoptosis
(Ventura et al., 2006). In the current study following
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Fig. 5. SP600125 (SP, 30mg/kg i.p.) potentiates the striatal neuronal apoptosis induced by METH (4mg/kg, i.p., 3 times at 3 h
intervals). SP600125 was administered 30min before the last dose of METH. (a) Photomicrograph of striatal sections stained for
TUNEL from mice 24 h after treatment. Bar indicates 100 μM. (b) Histogram shows the number of TUNEL positive cells. Data
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METH there was a robust but transient increase in JNK1/2
phosphorylation in total brain lysates 1 h (Urrutia et al.,
2013) and 3 h (ElAli et al., 2012) after METH adminis-
tration, which disappeared within 24 h of METH
exposure.
In line with a deleterious effect of JNK1/2 inhibition,
our results show that SP600125 increases the glial
response induced by METH. GFAP staining is considered
to be a hallmark of neurotoxicity and has been closely
associated with METH or MDMA-induced striatal dopa-
minergic neurotoxicity (Fornai et al., 2004; Busceti et al.,
2008; Granado et al., 2011b; Ares-Santos et al., 2012).
Genetic inactivation of dopamine D1 or D2 receptors
prevents astrogliosis and provides protection against
the neurotoxic effects of METH (Granado et al., 2011a;
Ares-Santos et al., 2012). Microglial activation has also
been strongly associated with METH-induced dopamin-
ergic neurodegeneration in the striatum of mice (LaVoie
et al., 2004; Thomas et al., 2004a,b; Yamamoto et al.,
2010), and is considered another marker for amphetamine
neurotoxicity (Thomas et al., 2004b). In response to
neuronal injury, microglia develop into an activated
phenotype, characterized by a more ameboid-like shaped
cell, changes that are proportional to the magnitude of the
injury (Kreutzberg, 1996; Raivich et al., 1999). Activated
microglia could then be involved in METH-induced
neurotoxicity through the release of pro-inﬂammatory
cytokines and reactive oxygen and nitrogen species
which could potentiate neuronal injury. On the other
hand, minocycline administration attenuated microglial
activation but failed to protect fromMETH-induced dopa-
minergic neurotoxicity in mice striatum (Sriram et al.,
2006). In contrast, the radical scavenger edaravone pro-
tected dopaminergic terminals without affecting METH-
induced microglial activation (Kawasaki et al., 2006).
Regardless of whether or not glial activation is directly
related to METH-induced dopaminergic neurotoxicity,
our data show a strong relationship between gliosis and
the number of Fluoro-Jade positive cells, suggesting a
potential role of reactive microglia/astroglia in
METH-induced neuronal damage.
Very little is known about the regulation and role of
IL-15 in the brain. In a previous paper (Granado et al.,
2011b) we reported that METH-induced expression of
IL-15 was localized in astrocytes but not in microglia.
As SP600125 enhanced the METH-induced glial response,
we expected an increase in IL-15 immunoreactivity com-
pared with METH-injected animals. In contrast, we
observed that administration of SP600125 interfered
with the METH-induced increase in IL-15 immunoreac-
tivity in the mouse striatum, pointing to regulation of
the expression of this pleiotropic cytokine by the JNK
pathway. Interestingly, these same animals with reduced
IL-15 expression showed greater neurodegeneration sug-
gesting a protective role for this protein, in line with
some recent data reporting enhanced severity of
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intervals). SP600125 was administered 30min before the last dose of METH. (a) Photomicrographs of striatal sections stained for
IL-15 from mice 24 h after treatment. (b) Histogram shows the integrated density of IL-15 immunoreactivity staining. Data represent
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244 A. Urrutia et al.
experimental autoimmune encephalomyelitis in IL-15
knockout mice (Wu et al., 2010).
Our data indicate that, SP600125 a JNK inhibitor, does
not protect against the dopaminergic damage induced by
METH and, in fact, potentiates the glial response and the
striatal cell body loss caused by the drug. Therefore, con-
sidering the dual effects of JNK activation more studies
are required to clarify the putative role of JNK as a thera-
peutic target for preventing neuronal death.
Supplementary material
For supplementary material accompanying this paper,
visit http://dx.doi.org/10.1017/S1461145713000850
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